 Home > Medical News > Medical Research Articles > CStone Pharmaceuticals and Hengrui Pharmaceuticals reached a strategic cooperation and exclusive license agreement for CS1002 (anti-CTLA-4 monoclonal antibody) in the Greater China region

CStone Pharmaceuticals and Hengrui Pharmaceuticals reached a strategic cooperation and exclusive license agreement for CS1002 (anti-CTLA-4 monoclonal antibody) in the Greater China region

 Last Update: 2022-01-04
 Source: Internet
 Author: User

Tags

gene drive mosquito

global holding

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CStone Pharmaceuticals granted Hengrui Pharmaceuticals an exclusive license to develop, register, produce and commercialize CS1002 (anti-CTLA-4 monoclonal antibody) in the Greater China region
CStone Pharmaceuticals will retain the right to develop and commercialize CS1002 (anti-CTLA-4 monoclonal antibody) outside of Greater China
CStone Pharmaceuticals and Hengrui Pharmaceuticals have joined forces to leverage their respective strengths in innovative R&D and commercial marketing to accelerate the subsequent development and commercialization of the tumor immune framework product CS1002 (anti-CTLA-4 monoclonal antibody), and maximize its market value

Suzhou, November 21, 2021/PRNewswire/ - CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616), a leading biopharmaceutical company focusing on research, development and commercialization of innovative tumor immunotherapies and precision therapeutic drugs, today Announced that it has reached a strategic cooperation and exclusive license agreement with Hengrui Medicine (600276.

According to the terms of the agreement, CStone Pharmaceuticals will be eligible to receive a total of approximately US$200 million in down payment and potential milestone payments, as well as double-digit royalties

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is one of the few clinically proven targets for tumor immunotherapy

Dr.

About CS1002 (anti-CTLA-4 monoclonal antibody)

CS1002 is an anti-CTLA-4 monoclonal antibody developed by CStone Pharmaceuticals

About CStone Pharmaceuticals

CStone Pharmaceuticals (Hong Kong Stock Exchange Code: 2616) is a biopharmaceutical company that focuses on research, development and commercialization of innovative tumor immunotherapy and precision treatment drugs to meet the ardent medical needs of cancer patients in China and around the world

For more information, please visit.

About Hengrui Medicine

Founded in 1970, Hengrui Medicine is a national pharmaceutical company engaged in the development and promotion of innovative and high-quality drugs.

Forward-looking statement

The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.